Literature DB >> 21985949

Change in high-density lipoprotein cholesterol and risk of subsequent hospitalization for coronary artery disease or stroke among patients with type 2 diabetes mellitus.

Gregory A Nichols1, Suma Vupputuri, A Gabriela Rosales.   

Abstract

The association between the changes in high-density lipoprotein (HDL) cholesterol and the risk of cardiovascular (CVD) or cerebrovascular hospitalization among patients with type 2 diabetes remains unclear. We conducted a retrospective observational cohort study of 30,067 members of the Kaiser Permanente Northwest and Georgia regions, who had type 2 diabetes and 2 HDL cholesterol measurements 6 to 24 months apart in 2001 to 2006. We followed up the cohort for ≤8 years (through 2009) to determine whether the change in HDL cholesterol was associated with subsequent CVD hospitalization. We examined the HDL cholesterol change continuously and by 3 categories: HDL cholesterol increased ≥6.5 mg/dl, decreased ≥6.5 mg/dl, or remained within ±6.4 mg/dl. The Cox regression models were adjusted for the baseline HDL cholesterol and demographic and clinical risk factors. During a mean follow-up of 55.8 ± 23.8 months, 3,023 patients (10.1%) experienced a CVD hospitalization. After multivariate adjustment, each 5 mg/dl of baseline HDL cholesterol was significantly associated with a 6% lower CVD hospitalization risk (hazard ratio 0.94 per 5 mg/dl, 95% confidence interval 0.92 to 0.95, p <0.0001) and each 5-mg/dl increase in HDL cholesterol was associated with a 4% CVD risk reduction (hazard ratio 0.96, 95% confidence interval 0.94 to 0.99, p <0.003). In the categorical analysis, a ≥6.5-mg/dl HDL cholesterol decrease was associated with an 11% increased CVD risk (hazard ratio 1.11, 95% confidence interval 1.00 to 1.24, p = 0.047) and a ≥6.5-mg/dl increase was associated with an 8% CVD risk reduction (hazard ratio 0.92, 95% confidence interval 0.84 to 1.01, p = 0.077) relative to those with stable HDL cholesterol. In conclusion, our results add to the growing body of evidence that increasing the HDL cholesterol levels might be an important strategy for CVD risk reduction. The prevention of HDL cholesterol decreases could be equally important.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21985949     DOI: 10.1016/j.amjcard.2011.05.047

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  8 in total

1.  A nutrient-dense, high-fiber, fruit-based supplement bar increases HDL cholesterol, particularly large HDL, lowers homocysteine, and raises glutathione in a 2-wk trial.

Authors:  Michele L Mietus-Snyder; Mark K Shigenaga; Jung H Suh; Swapna V Shenvi; Ashutosh Lal; Tara McHugh; Don Olson; Joshua Lilienstein; Ronald M Krauss; Ginny Gildengoren; Joyce C McCann; Bruce N Ames
Journal:  FASEB J       Date:  2012-05-01       Impact factor: 5.191

Review 2.  Vascular smooth muscle function in type 2 diabetes mellitus: a systematic review and meta-analysis.

Authors:  David Montero; Guillaume Walther; Antonia Pérez-Martin; Nestor Vicente-Salar; Enrique Roche; Agnès Vinet
Journal:  Diabetologia       Date:  2013-07-18       Impact factor: 10.122

3.  Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone.

Authors:  Graziella E Ronsein; Gissette Reyes-Soffer; Yi He; Michael Oda; Henry Ginsberg; Jay W Heinecke
Journal:  Mol Cell Proteomics       Date:  2015-12-14       Impact factor: 5.911

4.  Low high-density lipoprotein cholesterol is a residual risk factor associated with long-term clinical outcomes in diabetic patients with stable coronary artery disease who achieve optimal control of low-density lipoprotein cholesterol.

Authors:  Manabu Ogita; Katsumi Miyauchi; Tadashi Miyazaki; Ryo Naito; Hirokazu Konishi; Shuta Tsuboi; Tomotaka Dohi; Takatoshi Kasai; Takayuki Yokoyama; Shinya Okazaki; Takeshi Kurata; Hiroyuki Daida
Journal:  Heart Vessels       Date:  2013-03-21       Impact factor: 2.037

5.  Impact of serum nutritional status on physical function in african american and caucasian stroke survivors.

Authors:  Monica C Serra; Charlene E Hafer-Macko; Frederick M Ivey; Richard F Macko; Alice S Ryan
Journal:  Stroke Res Treat       Date:  2014-10-29

6.  Effects of BMI and LDL-cholesterol change pattern on cardiovascular disease in normal adults and diabetics.

Authors:  Tae Mi Youk; Min Jin Kang; Sun Ok Song; Eun-Cheol Park
Journal:  BMJ Open Diabetes Res Care       Date:  2020-12

7.  Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial.

Authors:  Peter E Linz; Laura C Lovato; Robert P Byington; Patrick J O'Connor; Lawrence A Leiter; Daniel Weiss; Rex W Force; John R Crouse; Faramarz Ismail-Beigi; Debra L Simmons; Vasilios Papademetriou; Henry N Ginsberg; Marshall B Elam
Journal:  Diabetes Care       Date:  2013-12-02       Impact factor: 19.112

8.  Patterns of engagement with the health care system and risk of subsequent hospitalization amongst patients with diabetes.

Authors:  Paul E Ronksley; Pietro Ravani; Claudia Sanmartin; Hude Quan; Braden Manns; Marcello Tonelli; Brenda R Hemmelgarn
Journal:  BMC Health Serv Res       Date:  2013-10-09       Impact factor: 2.655

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.